President's Page: Drug-Eluting Stents in Contemporary Practice-A Call for a Real-World, Open-Entry, Device-Tracking Registry

Journal of the American College of Cardiology

Volumn 49, Issue 22, 2007, Pages 2223-2226

  Dove, James T ^d   Moliterno, David J ^a   Weaver, W Douglas ^b   Shelton, Marc E ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL;

DEVICE; DRUG ELUTING STENT; EDITORIAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL SOCIETY; MEDICARE; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; RESTENOSIS; RISK BENEFIT ANALYSIS;

COATED MATERIALS, BIOCOMPATIBLE; CORONARY THROMBOSIS; DATA COLLECTION; DATABASES, FACTUAL; HUMANS; REGISTRIES; STENTS;

EID: 34250002833     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.05.005     Document Type: Editorial

References (13)

1. Babapulle M.N., Joseph L., Bélisle P., et al. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
2. Bavry A.A., Kumbhani D.J., Helton T.J., et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
3. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 48 (2006) 2584-2591
4. Summary from the Circulatory System Devices Panel Meeting, December 7-8, 2006. U.S. Food and Drug Administration. Available at: http://www.fda.gov/cdrh/panel/summary/circ-120706.html. Accessed December 12, 2006.
5. Rao S.V., Shaw R.E., Brindis R.G., et al. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. Am Heart J 152 (2006) 321-326
6. Carrozza J.P. Duration of clopidogrel therapy with drug-eluting stents. J Interven Cardiol 19 (2006) S40-S46
7. Mauri L., Hsieh W., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
8. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
9. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-668
10. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
11. Bliden K.P., DiChiara J., Tantry U.S., et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol 49 (2007) 657-666
12. Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. J Am Coll Cardiol 49 (2007) 734-739
13. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans-delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202